Curis, Inc. (CRIS) is a Lexington, Massachusetts-based clinical-stage biotechnology company developing emavusertib, an oral IRAK4 and FLT3 inhibitor being tested in combination with BTK inhibitors in primary central nervous system lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL). The stock traded at $0.5101 in Thursday's session, a decline of 16.96% from the previous close of $0.6143. The direction was unambiguously negative, and it erased a meaningful slice of the two-day advance that had lifted shares from $0.4358 on Monday to $0.6143 on Wednesday. No fresh press release, SEC filing, or analyst action explained the pullback; the move is best read as profit-taking in a low-float micro-cap after a sharp, news-driven run.
Wednesday's gain of 13.38% came on more than 1.5 million shares and followed Tuesday's 24.32% jump — a combined advance of about 41% in two sessions, during which the stock briefly traded above the $1.00 threshold in pre-market activity. Moves of that scale in a name with a float of only a few million shares typically attract short-horizon momentum capital, and that capital is quick to exit.
Thursday's tape fits that pattern rather than a fundamental reassessment: the decline began in the opening half hour and accelerated through the morning, with no disclosure to match. When a rally is built on positioning and anticipation rather than a change in intrinsic value, the unwind frequently retraces a large portion of the advance without a catalyst of its own.
At a virtual special meeting on November 18, stockholders approved amendments authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-12, with the board choosing the final ratio and timing within six months. The company has framed the step as necessary to lift the share price above Nasdaq's $1.00 minimum bid requirement.
That approval is a compliance mechanism, not an improvement in the business. It follows a November 2 staff determination that the bid price had closed below $1.00 for 30 consecutive business days, a finding made more severe because Curis completed a 1-for-20 reverse split on July 6, 2026 and was therefore ineligible for a standard cure period. The company remains under a one-year discretionary panel monitor imposed after a July 24 hearing decision and has said it intends to request a new hearing, while cautioning that there is no assurance the appeal succeeds or that shares stay listed. For investors, a confirmed split plus an unresolved delisting question is a reason to reduce exposure into strength, not add to it.
Third-quarter results, reported November 12, showed no revenue, a net loss of $8.1 million, and cash and equivalents of $5.0 million at September 30. Together with roughly $7.5 million in net proceeds from an October private placement, management projects funding into the first quarter of 2027 — a runway that leaves little margin for error. The operating thesis rests almost entirely on emavusertib: management disclosed 12 patients enrolled across 11 sites in the TakeAim CLL study, with initial data expected by the end of 2026, and full PCNSL enrollment targeted by the end of 2027. An analyst price target was cut sharply on November 13 following the share-count increase from the placement, a reminder that dilution remains a live constraint on valuation.
Roughly 300,000 shares had changed hands by midday, a pace well below the elevated turnover of the prior two sessions and broadly in line with the stock's recent baseline, indicating that the selling was not accompanied by a fresh institutional event. The move was idiosyncratic: broader equity indices and small-cap biotech benchmarks did not decline in comparable fashion, so sector sympathy does not explain the magnitude.
Technically, the pullback stalled near $0.5060, an area that had acted as resistance in mid-November before the breakout, and the price slipped back below its short-term moving averages after briefly reclaiming them. The stock remains roughly 96% lower year-to-date and far below its 200-day trend, so the rally was a countertrend bounce rather than a trend reversal.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Curis earns 22 out of 100. The verified news was procedural: shareholder approval of a reverse split designed to address a Nasdaq bid-price deficiency, material to listing status but not to the company's underlying value, and published before today's session. The decline was roughly 2.4 times the stock's average absolute daily move of about 7% over the past 60 sessions, but moves of that size or larger occurred seven times in that stretch. Modest news and a familiar-sized swing combine into a low score.
The central scheduled event is initial TakeAim CLL data, expected before year-end; the readout will be judged on signs of clinical activity in combination with zanubrutinib, and a disappointing result would carry outsized weight given the single-asset model. Management must also announce the reverse split ratio and effective date, file final vote results, and pursue its Nasdaq hearing. Investors should watch cash consumption against the first-quarter 2027 runway, any further warrant exercises or resale registration activity that could add supply, and commentary on PCNSL enrollment. Risks include continued dilution, potential delisting, thin liquidity that amplifies both directions, and binary clinical outcomes.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics, and traded symbols, so the lineup rotates as market conditions shift. Reviewing the current leaders can help traders compare disciplined, rules-based approaches against their own process — explore the page to see which automated strategies are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CRIS's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 70 similar instances where the Aroon Indicator showed a similar pattern. In 64 of the 70 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +40.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The 10-day RSI Indicator for CRIS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRIS as a result. In 70 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
CRIS moved below its 50-day moving average on November 09, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CRIS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.468) is normal, around the industry mean (3.596). P/E Ratio (0.248) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a drug company
Industry Biotechnology